Regulatory T Cells and Cancer: A Two-Sided Story |
| |
Authors: | Kepeng Wang Anthony T. Vella |
| |
Affiliation: | 1. Department of Immunology, School of Medicine, University of Connecticut Health Center, Farmington, CT, USAkewang@uchc.edu;3. Department of Immunology, School of Medicine, University of Connecticut Health Center, Farmington, CT, USA |
| |
Abstract: | ABSTRACTRegulatory T cells (Tregs) play pivotal roles in limiting the duration and magnitude of immune response against infectious agents and self-antigens. This is accomplished through contact-dependent and -independent mechanisms that involve crosstalk between Treg cells and other immune and tissue-specific cell types. The same machinery is employed by Tregs to regulate immune responses to cancer, limiting both pro-tumor inflammation and anti-tumor immunity. Factors produced by Treg cells also act directly on transformed epithelial cells and exert opposing effects during different stages of cancer development. Therefore, the immune regulatory cell population serves as a double-edged sword for the development, progression, and treatment of cancers. In this review, we summarize current knowledge on the roles of Treg lymphocytes during cancer development, as well as the underlying cellular and molecular mechanism. |
| |
Keywords: | Cancer immunotherapy cytokines inflammation regulatory T cells |
|
|